The druggable genome
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
An assessment of the number of molecular targets that represent an opportunity for therapeutic intervention is crucial to the development of post-genomic research strategies within the pharmaceutical industry. Now that we know the size of the human genome, it is interesting to consider just how many molecular targets this opportunity represents. We start from the position that we understand the properties that are required for a good drug, and therefore must be able to understand what makes a good drug target.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The dataset adds high-quality structural models across a broad range of Gene Ontology (GO) terms36,37, including pharmaceutically relevant classes such as enzymes and membrane proteins38 (Fig. 1d).”
From Highly accurate protein structure prediction for the human proteome (2021) · cites this paper as [38]
In the citing paper
“Proteins have several additional advantages as they are most often the direct mediators of biological processes and form the vast majority of currently druggable targets in disease160.”
From Measuring biological age using omics data (2022) · cites this paper as [160]
In the citing paper
“Only around 20% of the human proteome is considered to be druggable with small-molecule antagonists.”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [2]
In the citing paper
“Although this has been a highly effective approach, it has left potential drug targets undrugged or underdrugged45.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [45]
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760 · cited 1×
“identified 483 targets, and concluded that there could be 5,000–10,000 potential targets on the basis of an estimate of the number of disease-related gene”
BackgroundMetabolite profiling for plant functional genomics
Fiehn, O., Kopka, J., Dörmann, P., Altmann, T., Trethewey, R. N., & Willmitzer, L. (2000) · Nature Biotechnology · doi:10.1038/81137 · Cited by 2,127 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundComparative Genomics of the Eukaryotes
Rubin, G. M., Yandell, M. D., Wortman, J. R., Gabor, G. L., Miklos, Nelson, C. R., Hariharan, I. K., Fortini, M. E., Li, P. W., Apweiler, R., et al. (2000) · Science · doi:10.1126/science.287.5461.2204 · Cited by 1,698
Apweiler, R. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.37 · Cited by 1,079
A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations
Raamsdonk, L. M., Teusink, B., Broadhurst, D., Zhang, N., Hayes, A., Walsh, M. C., Berden, J. A., Brindle, K. M., Kell, D. B., Rowland, J. J., et al. (2001) · Nature Biotechnology · doi:10.1038/83496 · Cited by 1,005 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundTweeddale, H., Notley-McRobb, L., & Ferenci, T. (1998) · Journal of Bacteriology · doi:10.1128/jb.180.19.5109-5116.1998 · Cited by 393 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
Background
Cited by
Items 801–900 of 1,029
Chen, P., Li, X., Sun, Y.-L., Liu, Z., Cao, R., He, Q., Wang, M., Xiong, J., Xie, J., Wang, X., et al. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03934.x · Cited by 59
Second-generation kinase inhibitors
Klebl, B., & Müller, G. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.5.975 · Cited by 61
“It further experienced a surprise considering that the protein kinase family was regarded as a family of non-druggable targets in the mid-1990s and matured to one of the most populated target gene families [7].”
BackgroundInfluentialAccurate prediction of deleterious protein kinase polymorphisms
Torkamani, A., & Schork, N. J. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm437 · Cited by 65
“For the creation of the natural set, all disease causing (DCs) SNPs were taken from published literature compiled in OMIM, KinMutBase and the Human Gene Mutation Database (HMGD).”
MethodRNAi and HTS: exploring cancer by systematic loss-of-function
Willingham, A. T., Deveraux, Q. L., Hampton, G. M., & Aza‐Blanc, P. (2004) · Oncogene · doi:10.1038/sj.onc.1208217 · Cited by 59
“There are an estimated 3000 disease-modifying genes present in the human genome, yet to date, the pharmaceutical industry has only focused their efforts on about 500 (reviewed in Hopkins and Groom, 2002).”
BackgroundCytosolic delivery of proteins by cholesterol tagging
Tai, W., Zhao, P., & Gao, X. (2020) · Science Advances · doi:10.1126/sciadv.abb0310 · Cited by 59
Keränen, H., Gutiérrez‐de‐Terán, H., & Åqvist, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108492 · Cited by 58
“to the superfamily of G-protein coupled receptors (GPCRs), which have been consequently identified as targets for about 30% of all marketed drugs [1].”
BackgroundRasche, A., Al‐Hasani, H., & Herwig, R. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-310 · Cited by 71
“druggable) compounds [58,59].”
Candelaria, N. R., Addanki, S., Zheng, J., Nguyen-Vu, T., Karaboga, H., Dey, P., Gabbi, C., Vedin, L., Ka, L., Wu, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106289 · Cited by 63
“Members of the nuclear receptor (NR) superfamily of liganddependent transcription factors carry out vital cellular functions and are highly druggable targets [7].”
BackgroundGuan, Y., Shan, X., Zhang, F., Wang, S., Chen, H., & Tao, N. J. (2015) · Science Advances · doi:10.1126/sciadv.1500633 · Cited by 59
Self-assembly in elastin-like recombinamers: a mechanism to mimic natural complexity
Quintanilla-Sierra, L., García-Arévalo, C., & Rodriguez-Cabello, J. C. (2019) · Materials Today Bio · doi:10.1016/j.mtbio.2019.100007 · Cited by 54
Surade, S. B., Klein, M., Stolt-Bergner, P. C., Muenke, C., Roy, A., & Michel, H. (2006) · Protein Science · doi:10.1110/ps.062312706 · Cited by 58
“In addition, their importance is enhanced by the fact that a large number of today’s drugs are targeted at membrane proteins (Hopkins and Groom 2002; McKeegan et al. 2002).”
BackgroundAdvances in algal drug research with emphasis on enzyme inhibitors
Rengasamy, K. R. R., Kulkarni, M. G., Stirk, W. A., & Staden, J. V. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.08.005 · Cited by 58
Gjoni, T., & Urwyler, S. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.008 · Cited by 58
hGPR87 contributes to viability of human tumor cells
Glatt, S., Halbauer, D., Heindl, S., Wernitznig, A., Kozina, D. S., Su, K.-C., Puri, C., Garin‐Chesa, P., & Sommergruber, W. (2008) · International Journal of Cancer · doi:10.1002/ijc.23349 · Cited by 57
Engineering an Ultra-Thermostable β1-Adrenoceptor
Miller, J. L., & Tate, C. G. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.08.057 · Cited by 57
“opyright © 2011 Published b GPCRs are therefore required, preferably in different conformations, to understand how they function and to design new therapeutic compounds.(2,3) In an ideal world, pharmaceutical companies would like structures of GPCRs to be available bound to different agonists and antagonists or bound…”
Wong, S. S. W., Samaranayake, L. P., & Seneviratne, C. J. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.06.009 · Cited by 65
Understanding the Molecular Properties and Metabolism of Top Prescribed Drugs
Zhong, H., Mashinson, V., Woolman, T. A., & Zha, M. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990034 · Cited by 57
Moore‐Morris, T., Varrault, A., Mangoni, M. E., Digarcher, A. L., Nègre, V., Dantec, C., Journot, L., Nargeot, J., & Couette, B. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.054155 · Cited by 57
“Indeed, approximately 30 to 40% of prescriptions drugs act on GPCRs, but these highly targeted receptors represent only a small percentage of known GPCRs (Hopkins and Groom, 2002).”
BackgroundApplications of miRNAs in cardiac development, disease progression and regeneration
Pang, J. K. S., Phua, Q. H., & Soh, B.-S. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1451-2 · Cited by 59
Lamichhane, R., Liu, J. J., White, K. L., Katritch, V., Stevens, R. C., Wüthrich, K., & Millar, D. P. (2020) · Structure · doi:10.1016/j.str.2020.01.001 · Cited by 57
The mechanism of action and clinical value of PROTACs: A graphical review
Graham, H. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110446 · Cited by 60
“Figure sourced from Hopkins and Groom [18].”
Ísberg, V., Andersen, K. B., Bisig, C., Dietz, G. P. H., Bräuner‐Osborne, H., & Gloriam, D. E. I. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500197a · Cited by 62
Bello, M. L., Chiaradia, L. D., Dias, L. R. S., Pacheco, L. K., Stumpf, T. R., Mascarello, A., Steindel, M., Yunes, R. A., Castro, H. C., Nunes, R. J., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.023 · Cited by 56
Zhang, T., Fu, J., Geng, Z., Yang, J., & Sun, X. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12015 · Cited by 57
“These strategies have successfully targeted dozens of GPCRs in the discovery of new therapeutic agents [1].”
BackgroundThe gating charge pathway of an epilepsy-associated potassium channel accommodates chemical ligands
Li, P., Chen, Z., Xu, H., Sun, H., Li, H., Liu, H., Yang, H., Gao, Z., Jiang, H., & Li, M. (2013) · Cell Research · doi:10.1038/cr.2013.82 · Cited by 56
Reprogramming chaperone pathways to improve membrane protein expression in Escherichia coli
Nannenga, B. L., & Baneyx, F. (2011) · Protein Science · doi:10.1002/pro.669 · Cited by 65
Deep interactome profiling of membrane proteins by co-interacting protein identification technology
Pankow, S., Bamberger, C., Calzolari, D., Bamberger, A., & Yates, J. R. (2016) · Nature Protocols · doi:10.1038/nprot.2016.140 · Cited by 60
K-RasG12D Has a Potential Allosteric Small Molecule Binding Site
Feng, H., Zhang, Y., Bos, P. H., Chambers, J. M., Dupont, M. M., & Stockwell, B. R. (2019) · Biochemistry · doi:10.1021/acs.biochem.8b01300 · Cited by 57
Profiling the Membrane Proteome of Shewanella oneidensis MR-1 with New Affinity Labeling Probes
Tang, X., Yi, W., Munske, G. R., Adhikari, D. P., Zakharova, N. L., & Bruce, J. E. (2007) · Journal of Proteome Research · doi:10.1021/pr060480e · Cited by 57
Recent advances in 17beta-hydroxysteroid dehydrogenases
Prehn, C. P., Möller, G., & Adamski, J. (2009) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2008.12.024 · Cited by 64
A structural biology view of target drugability
Egner, U., & Hillig, R. C. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.4.391 · Cited by 56
“The pioneering publication by Hopkins and Groom in 2002 introducing the concept of the ‘drugable genome’ inspired scientists in both academic institutions and the pharmaceutical industry to focus on the research of drugable proteins and explore the characteristics of drug targets [3] .”
BackgroundInfluentialBacMam Recombinant Baculoviruses in G Protein?Coupled Receptor Drug Discovery
Ames, R. S., Fornwald, J. A., Nuthulaganti, P., Trill, J. J., Foley, J. J., Buckley, P. T., Kost, T. A., Wu, Z., & Romanos, M. A. (2004) · Receptors and Channels · doi:10.1080/10606820490514969 · Cited by 56
The promise of genomics to identify novel therapeutic targets
Orth, A. P., Batalov, S., Perrone, M. H., & Chanda, S. K. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.6.587 · Cited by 59
“Because both this and previous analyses [6] have forecast protein families utilising an InterPro domain-mapping strategy, these figures may represent an overestimation of the actual number of druggable genes.”
BackgroundResultInfluentialJing, S., Kong, X., Wang, L., Wang, H., Feng, J., Wei, L., Meng, Y., Liu, C., Chang, X., Qu, Y., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02340-21 · Cited by 58
“70 1023 s21, respectively, in the ligand- within the hierarchy of protein interactions (24).”
Komatsu, T., & Urano, Y. (2015) · Analytical Sciences · doi:10.2116/analsci.31.257 · Cited by 57
van Westen, G. J. P., Wegner, J. K., Geluykens, P., Kwanten, L., Vereycken, I., Peeters, A., IJzerman, A. P., van Vlijmen, H., & Bender, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027518 · Cited by 56
Ireland, P. M., McMahon, R. M., Marshall, L. E., Halili, M. A., Furlong, E., Tay, S. V., Martin, J. L., & Sarkar‐Tyson, M. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5375 · Cited by 55
“Targeting protein–protein interactions of this nature is challenging, as these typically flat protein surfaces lack the characteristic deep cavities and active site pockets of the so-called ‘‘druggable genome’’ (36).”
BackgroundKooistra, A. J., Leurs, R., de Esch, I. J. P., & de Graaf, C. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00066 · Cited by 55
Virus-Host Interactions: From Unbiased Genetic Screens to Function
Ramage, H. R., & Cherry, S. R. (2015) · Annual Review of Virology · doi:10.1146/annurev-virology-100114-055238 · Cited by 58
“The so-called druggable genome is a particularly attractive target, as it comprises cellular factors that are thought to be amenable to therapeutic intervention (19).”
BackgroundIdentification of human drug targets using machine-learning algorithms
Kumari, P., Nath, A., & Chaube, R. (2014) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2014.11.008 · Cited by 56
“Sequence homology and domain search methods of existing drug target families have been developed to identify new drug targets [5].”
BackgroundConformational ensembles, signal transduction and residue hot spots: application to drug discovery.
Acuner, S. E., Gürsoy, A., Keskin, Ö., & Nussinov, R. (2010) · PubMed · Cited by 65
Resveratrol directly targets DDX5 resulting in suppression of the mTORC1 pathway in prostate cancer
Taniguchi, T., Iizumi, Y., Watanabe, M., Masuda, M., Morita, M., Aono, Y., Toriyama, S., Oishi, M., Goi, W., & Sakai, T. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.114 · Cited by 58
“Furthermore, identifying the direct targets of resveratrol is expected to lead to the discovery of druggable targets.(19) Resveratrol modulates multiple signaling pathways, for example, by inhibiting the mammalian target of rapamycin complex 1 (mTORC1) pathway.”
BackgroundRunx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression
Gowda, P. S., Wildman, B. J., Trotter, T. N., Xu, X., Hao, X., Hassan, M. Q., & Yang, Y. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0606 · Cited by 52
“Unfortunately, transcription factors are often considered to be non-druggable, as targeting these intracellular proteins lacking enzymatic activity remains challenging (11, 12).”
BackgroundSgourakis, N. G., Bagos, P. G., Papasaikas, P., & Hamodrakas, S. J. (2005) · BMC Bioinformatics · doi:10.1186/1471-2105-6-104 · Cited by 65
“Indeed, over 50% of all prescribed drugs target on GPCRs [35].”
BackgroundEvanics, F., Hwang, P. M., Cheng, Y., Kay, L. E., & Prosser, R. S. (2006) · Journal of the American Chemical Society · doi:10.1021/ja0610075 · Cited by 55
Chick, J. M., Haynes, P. A., Molloy, M. P., Bjellqvist, B., Baker, M. S., & Len, A. C. L. (2008) · Journal of Proteome Research · doi:10.1021/pr700611w · Cited by 61
Peptide‐based covalent inhibitors of protein–protein interactions
Paulussen, F. M., & Grossmann, T. N. (2022) · Journal of Peptide Science · doi:10.1002/psc.3457 · Cited by 58
Chemoproteomics, A Broad Avenue to Target Deconvolution
Gao, Y., Ma, M., Li, W., & Lei, X. (2023) · Advanced Science · doi:10.1002/advs.202305608 · Cited by 61
Positive selection of primate genes that promote HIV-1 replication
Meyerson, N. R., Rowley, P. A., Swan, C. H., Le, D. T., Wilkerson, G. K., & Sawyer, S. L. (2014) · Virology · doi:10.1016/j.virol.2014.02.029 · Cited by 60
“…of positive selection in our study, ANKRD30A is one of the few candidate HIV host factors that has been categorized as a “druggable” target, based on properties that it shares with proteins that have been already successfully targeted by drugs (Bushman et al., 2009; Hopkins and Groom, 2002).”
Han, C., Chen, J.-S., Chan, E., Wu, C.-P., Yu, K., Chen, K.-T., Tsou, C., Tsai, C.-F., Chien, C.-W., Kuo, Y., et al. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.003087 · Cited by 58
“Most of the FDA-approved cancer biomarker, such as CEA and CA19–9, and (cid:1) 70% of all known pharmaceutical drug targets are mainly membrane proteins (28).”
BackgroundComputational and Experimental Prediction of Human C-Type Lectin Receptor Druggability
Aretz, J., Wamhoff, E., Hanske, J., Heymann, D., & Rademacher, C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00323 · Cited by 58
“The term druggability, however, refers to the ability of a protein to bind a drug-like ligand with high affinity and specificity (29–31).”
BackgroundDruggability analysis and classification of protein tyrosine phosphatase active sites
Ghattas, M. A., Raslan, N., Sadeq, A., Sorkhy, M. A., & Atatreh, N. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s111443 · Cited by 54
“The term “druggable” was defined previously by Hopkins and Groom 19 as a protein that is able, or predicted to be able, to bind drug-like molecules.”
Campuzano, I. D. G., Li, H., Bagal, D., Lippens, J. L., Svitel, J., Kurzeja, R. J. M., Xu, H., Schnier, P. D., & Loo, J. A. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b03762 · Cited by 54
Iegre, J., Gaynord, J. S., Robertson, N., Sore, H. F., Hyvönen, M., & Spring, D. R. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800052 · Cited by 55
Segers, K., Spérandio, O., Sack, M., Fischer, R., Miteva, M. A., Rosing, J., Nicolaes, G. A. F., & Villoutreix, B. O. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701051104 · Cited by 59
Haitina, T., Fredriksson, R., Foord, S. M., Schiöth, H. B., & Gloriam, D. E. I. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-24 · Cited by 60
“GPCRs represent between 30-45% of the current drug targets [12,13] and many pharmaceutical companies devote up to 30% of their drug discovery efforts toward them [14].”
BackgroundNakajima, T., Iikura, M., Okayama, Y., Matsumoto, K., Yoshimura-Uchiyama, C., Shirakawa, T., Yang, X., Adra, C. N., Hirai, K., & Saito, H. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.12.036 · Cited by 54
Spontaneous Formation of Detergent Micelles around the Outer Membrane Protein OmpX
Böckmann, R. A., & Caflisch, A. (2005) · Biophysical Journal · doi:10.1529/biophysj.105.060426 · Cited by 56
“However, despite the relative abundance of membrane proteins among all proteins and despite the fact that they represent the majority of the targets for existing drugs (Hopkins and Groom, 2002; Sanders and Myers, 2004), only few structures have been solved.”
Targeting G protein coupled receptor-related pathways as emerging molecular therapies
Ghanemi, A. (2015) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.07.007 · Cited by 53
“Indeed, several papers have indicated that this portion is between 30% and 60% (Hopkins and Groom, 2002; Lundstrom, 2006), whereas authors have estimated that nearly half of the pharmakons interact directly or indirectly with these 7 transmembrane receptors (7TMRs) (Heilker et al.”
Aptamers for Viral Detection and Inhibition
Chakraborty, B., Das, S., Gupta, A., Xiong, Y., T-V, V., Kizer, M. E., Duan, J., Chandrasekaran, A. R., & Wang, X. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00546 · Cited by 59
Yin, K., Chen, T., Gu, X., Su, W., Jiang, Z., Lu, S., Cao, B., Chi, L., Gao, X., & Chen, Y. (2024) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13479 · Cited by 59
“12 Furthermore, research on the ‘ Druggable genome ’ can expedite the drug development process, providing more information and guidance for drug design.”
BackgroundGlobal Analysis of Small Molecule Binding to Related Protein Targets
Krüger, F. A., & Overington, J. P. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002333 · Cited by 56
“often organized conceptually around pharmacologically successful gene families (such as nuclear receptors, rhodopsin-like GPCRs, various ion-channel families, and most recently, protein kinases) [4,5], leveraging known data to develop novel selective chemotypes is of fundamental importance.”
BackgroundMulti-Step Usage of in Vivo Models During Rational Drug Design and Discovery
Williams, C. H., & Hong, C. C. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12042262 · Cited by 53
“thought to be disease causing [2].”
Distinctive Behaviors of Druggable Proteins in Cellular Networks
Mitsopoulos, C., Schierz, A. C., Workman, P., & Al-Lazikani, B. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004597 · Cited by 53
Mechanisms of cyanobactin biosynthesis
Czekster, C. M., Ge, Y., & Naismith, J. H. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.08.029 · Cited by 56
“Despite approximately 3000 human genes having been estimated to be involved in disease states, only a fraction (between 20 and 50 %) are thought to be potentially responsive to inhibition by traditional small molecule drugs [1].”
BackgroundTarget Control in Logical Models Using the Domain of Influence of Nodes
Yang, G., Zañudo, J. G. T., & Albert, R. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00454 · Cited by 58
“However, gene knockout, pharmacological inhibition of proteins and providing sustained external signals have been robustly implemented and demonstrated to be effective intervention strategies (Hopkins and Groom, 2002; Nicholl, 2008; Shalem et al., 2014).”
BackgroundRecent advances in screening of enzymes inhibitors based on capillary electrophoresis
Cheng, M., & Chen, Z. (2018) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2018.05.002 · Cited by 53
Tian, Y. P., Tirrell, M., & LaBelle, J. L. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102600 · Cited by 57
Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases.
Kischel, P., Bellahcène, A., Deux, B., Lamour, V., Dobson, R., Pauw, E. D., Clézardin, P., & CASTRONOVO, V. (2012) · PubMed · Cited by 53
Singh, S., Gras, A., Fiez-Vandal, C., Ruprecht, J. J., Rana, R. R., Martínez, M., Strange, P. G., Wagner, R., & Byrne, B. (2008) · Microbial Cell Factories · doi:10.1186/1475-2859-7-28 · Cited by 53
Microscale NMR Screening of New Detergents for Membrane Protein Structural Biology
Zhang, Q., Horst, R., Geralt, M., Ma, X., Hong, W., Finn, M. G., Stevens, R. C., & Wüthrich, K. (2008) · Journal of the American Chemical Society · doi:10.1021/ja077863d · Cited by 56
Involvement of Plasmodium falciparum protein kinase CK2 in the chromatin assembly pathway
Dastidar, E. G., Dayer, G., Holland, Z., Dorin, D., Claës, A., Chêne, A., Sharma, A. K., Hamelin, R., Moniatte, M., Lopez-Rubio, J.-J., et al. (2012) · BMC Biology · doi:10.1186/1741-7007-10-5 · Cited by 52
“Investigations of the druggability of the genome identified serine/ threonine PKs as one of the most promising groups for future small molecule inhibitors, comprising up to 20% of the druggable genome [9].”
BackgroundIdentification of Surrogate Agonists and Antagonists for Orphan G-Protein-Coupled Receptor GPR139
Hu, L. A., Tang, P. M., Eslahi, N. K., Zhou, T., Barbosa, J., & Liu, Q. (2009) · SLAS DISCOVERY · doi:10.1177/1087057109335744 · Cited by 52
“Even though GPCRs constitute only a small fraction (15%) of total druggable genes, they account for more than 30% of targets of marketed small-molecule drugs.(3) Due to the enormous historical success of GPCR drug targets, the search for new drugs targeting GPCRs is still the prime focus of many pharmaceutical compani…”
BackgroundGoddard, W. A., Kim, S., Li, Y., Trzaskowski, B., Griffith, A. R., & Abrol, R. (2010) · Journal of Structural Biology · doi:10.1016/j.jsb.2010.01.001 · Cited by 56
“They represent 30–50% of the current drug targets (Hopkins and Groom, 2002; Lundstrom, 2006), but a major impediment to developing active and selective therapeutics is the lack of structural data.”
BackgroundAbou-Gharbia, M. A., & Childers, W. E. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401564r · Cited by 58
Broomhead, N. K., & Soliman, M. E. S. (2016) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-016-0769-y · Cited by 57
Small-Molecule Inhibitors of the SOX18 Transcription Factor
Fontaine, F. R., Overman, J. P., Moustaqil, M. D., Mamidyala, S. K., Salim, A. A., Narasimhan, K., Prokoph, N., Robertson, A. A. B., Lua, L. H. L., Alexandrov, K. A., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.01.003 · Cited by 53
Molecular assembly of rhodopsin with G protein-coupled receptor kinases
He, Y., Gao, X., Goswami, D., Hou, L., Pal, K., Yin, Y., Zhao, G., Ernst, O. P., Griffin, P. R., Melcher, K., et al. (2017) · Cell Research · doi:10.1038/cr.2017.72 · Cited by 57
Advances in Capillary Electrophoresis-Based Enzyme Assays
Scriba, G. K. E., & Belal, F. F. (2015) · Chromatographia · doi:10.1007/s10337-015-2912-0 · Cited by 52
Capriles, P. V. Z., Guimarães, A. C., Otto, T. D., de Miranda, A. B., Dardenne, L. E., & Degrave, W. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-610 · Cited by 55
“Although therapeutic agents are also able to interact with polysaccharides, lipids and nucleic acids, protein inhibitors, particularly enzyme inhibitors, comprise about 47% of all drugs against pharmacological targets with commercial interest [13].”
BackgroundAustin, C. P. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104426 · Cited by 57
A cryptic pocket in Ebola VP35 allosterically controls RNA binding
Cruz, M. A., Frederick, T. E., Mallimadugula, U. L., Singh, S., Vithani, N., Zimmerman, M. I., Porter, J. R., Moeder, K. E., Amarasinghe, G. K., & Bowman, G. R. (2022) · Nature Communications · doi:10.1016/j.bpj.2021.11.2561 · Cited by 56
Enzyme function and evolution through the lens of bioinformatics
Ribeiro, A. J. M., Riziotis, I. G., Borkakoti, N., & Thornton, J. M. (2023) · Biochemical Journal · doi:10.1042/bcj20220405 · Cited by 59
Tackling Undruggable Targets with Designer Peptidomimetics and Synthetic Biologics
Swenson, C., Mandava, G., Thomas, D. M., & Moellering, R. E. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00423 · Cited by 63
Novel cAMP signalling paradigms: therapeutic implications for airway disease
Billington, C. K., & Hall, I. P. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01719.x · Cited by 50
“GPCRs constitute a significant target for pharmacological therapeutic intervention with ~30% of marketed small molecule drugs in clinical use directed at them (Hopkins and Groom, 2002).”
BackgroundQuantitative Analysis of Surface Plasma Membrane Proteins of Primary and Metastatic Melanoma Cells
Qiu, H., & Wang, Y. (2008) · Journal of Proteome Research · doi:10.1021/pr700651b · Cited by 64
McMorran, L. M., Brockwell, D., & Radford, S. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.02.011 · Cited by 55
Structural Mechanisms of Voltage Sensing in G Protein-Coupled Receptors
Vickery, O. N., Machtens, J., Tamburrino, G., Seeliger, D., & Zachariae, U. (2016) · Structure · doi:10.1016/j.str.2016.04.007 · Cited by 51
Zhang, P., Tao, L., Zeng, X. L., Chu, Q., Chen, S., Zhu, F., Li, Z., Jiang, Y., Chen, W., & Chen, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw071 · Cited by 53
“The targets of approved drugs possess such specific target-like characteristics as the appropriate druggable structures, substantial dissimilarity to human proteins and distinguished systems and tissue distribution profiles [9, 17, 96, 97].”
BackgroundGenetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment
Lewis, T. R., Shelton, E. L., Driest, S. L. V., Kannankeril, P. J., & Reese, J. (2018) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2018.02.006 · Cited by 51
“First, the protein would share sequence or structural similarities to many targets of existing drugs, thus conferring a likelihood of drug binding [82].”
BackgroundWang, C., Ge, X., Wang, M., Ma, T., Zhang, Y., & Lin, Y. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1529-x · Cited by 53
“GPCRs are also expressed within osteoblasts and osteoclasts, which are thought to be two opposite sides of a coin, and play a crucial role in modulating bone turnover, thus highlighting the potential for these receptors in the treatment of bone-related diseases, namely, osteoporosis, through a long-lasting enhancement…”
BackgroundThe hidden world of membrane microproteins
Makarewich, C. A. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.111853 · Cited by 54
“the importance of these proteins is highlighted by the fact that nearly half of all current therapeutic targets are membrane proteins [2, 3].”
BackgroundBoran, A. D. W., & Iyengar, R. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20191 · Cited by 56
“Drugs that target GPCRs comprise a single large island of 481 components.26 A majority of targets of currently approved drugs are GPCRs (~25%),5 which govern a diversity of physiological processes such as cardiac contractility, acid secretion, and airway constriction.”
BackgroundKeynote review: Disease-specific target selection: a critical first step down the right road
Roses, A. D., Burns, D. K., Chissoe, S. L., Middleton, L. T., & Jean, P. S. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03321-5 · Cited by 54
Comparative genomic assessment of novel broad‐spectrum targets for antibacterial drugs
White, T. A., & Kell, D. B. (2004) · Comparative and Functional Genomics · doi:10.1002/cfg.411 · Cited by 52
Expression and purification of milligram levels of inactive G-protein coupled receptors in E. coli
Bane, S. E., Velasquez, J. E., & Robinson, A. S. (2006) · Protein Expression and Purification · doi:10.1016/j.pep.2006.10.017 · Cited by 51
“3 % of available high-resolution protein structures [1, 2].”
BackgroundAdvancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence
Duran-Frigola, M., Cigler, M., & Winter, G. E. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11098 · Cited by 50
Zhu, F., Han, L., Zheng, C., Xie, B., Tammi, M. T., Yang, S., Wei, Y., & Chen, Y. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.149955 · Cited by 50
“These methods explore comparative sequence analysis (Hopkins and Groom, 2002), structural analysis (Hajduk et al., 2005), ligand-protein inverse docking (Chen and Zhi, 2001), machine learning of druggability characteristics (Zheng et al., 2006b), and system-related druggability profiles (Zheng et…”
BackgroundMethodInfluentialThe applications of deep learning algorithms on in silico druggable proteins identification
Yu, L., Xue, L., Liu, F., Li, Y., Jing, R., & Luo, J. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.01.009 · Cited by 54
“At present, increasing attention has been given to druggable proteins, which play a key role in various diseases and have proven to be one of the most important sources of drug targets [81].”
BackgroundTong, Y., Zhang, P., Yang, X., Liu, X., Zhang, J., Grudniewska, M., Jung, I., Abegg, D., Liu, J., Childs‐Disney, J. L., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2306682120 · Cited by 53
“Genome - wide analyses suggest that only 15% of proteins are in druggable families (1, 2).”
BackgroundMethodInfluential
Metadata
- Authors
- Hopkins, A. L., & Groom, C. R.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Groom, Colin R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-09
- Volume
- 1
- Issue
- 9
- Pages
- 727-730
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2074370114
- Cited by
- 3,305
- References
- 16
- Citations by year
- 2026: 91 · 2025: 113 · 2024: 131 · 2023: 116 · 2022: 155 · 2021: 150 · 2020: 144 · 2019: 147 · 2018: 136 · 2017: 132 · 2016: 144 · 2015: 182 · 2014: 162 · 2013: 161 · 2012: 212
- FWCI
- 70.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
- Keywords
- druggable genome, therapeutic target, molecular targets, target identification
- MeSH terms
- Biological Availability, Chemistry, Pharmaceutical, Humans, Molecular Biology, Pharmacokinetics, Genome, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.